Basal Markers and Prognosis in Luminal Breast Cancer

Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-017-4182-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Involvement of Metformin and AMPK in the Radioresponse and Prognosis of Luminal Versus Basal-Like Breast Cancer Treated With Radiotherapy

Oncotarget
Oncology
2014English

Active Smoking and Risk of Luminal and Basal-Like Breast Cancer Subtypes in the Carolina Breast Cancer Study

Cancer Causes and Control
Cancer ResearchOncology
2016English

ECT2 Associated to PRICKLE1 Are Poor-Prognosis Markers in Triple-Negative Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
2019English

Cytotoxic T Lymphocyte Associated Antigen 4 Expression Predicts Poor Prognosis in Luminal B HER2-negative Breast Cancer

Oncology Letters
Cancer ResearchOncology
2018English

Luminal-B Breast Cancer and Novel Therapeutic Targets

Breast Cancer Research
Cancer ResearchOncology
2011English

Breast Cancer Genes Don't Affect Prognosis in Breast Cancer

BMJ
2007English

The Suppression of DUSP5 Expression Correlates With Paclitaxel Resistance and Poor Prognosis in Basal-Like Breast Cancer

International Journal of Medical Sciences
Medicine
2018English

Sixteen-Kinase Gene Expression Identifies Luminal Breast Cancers With Poor Prognosis

Cancer Research
Cancer ResearchOncology
2008English

Histological Grading and Prognosis in Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
1957English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy